February 29th 2008
The U.S. Food and Drug Administration approved Nexium (esomeprazole magnesium) for short-term use in children ages 1-11 years for the treatment of gastroesophageal reflux disease (GERD). The agency approved Nexium in two forms, a delayed-release capsule and liquid form. Nexium is approved in 10 milligrams (mg) or 20 mg daily for children 1-11 years old compared to 20 mg or 40 mg recommended for pediatric patients 12 to 17 years of age.
February 29th 2008
The U.S. Food and Drug Administration approved Nexium (esomeprazole magnesium) for short-term use in children ages 1-11 years for the treatment of gastroesophageal reflux disease (GERD).
February 28th 2008
Article Examiner This is the most recent article version. WASHINGTON ( Map , News ) – The Food and Drug Administration has approved use of the drug Nexium in children aged 1 to 11 who have acid reflux disease.
February 28th 2008
WASHINGTON (AP) — The Food and Drug Administration has approved use of the drug Nexium in children aged 1 to 11 who have acid reflux disease. FDA said Thursday it approved liquid and delayed-release capsules of Nexium in doses of 10 milligrams or 20 milligrams for these youngsters.
February 28th 2008
Children under age 12 with acid reflux get FDA approval to take a drug originally meant for adults.
February 28th 2008
The FDA approves the use of an acid reflux drug in children.
February 28th 2008
Children under age 12 with acid reflux get FDA approval to take a drug originally meant for adults.
February 28th 2008
WASHINGTON (AP) — The Food and Drug Administration has approved use of the drug Nexium in children aged 1 to 11 who have acid reflux disease.
February 28th 2008
WASHINGTON – The Food and Drug Administration approved use of the drug Nexium today in children aged 1 to 11 who have acid reflux disease.
February 28th 2008
WASHINGTON – The Food and Drug Administration has approved use of the drug Nexium in children aged 1 to 11 who have acid reflux disease. FDA said Thursday it approved liquid and delayed-release capsules of Nexium in doses of 10 milligrams or 20 milligrams for these youngsters.
February 28th 2008
The Food and Drug Administration has approved use of the drug Nexium in children aged 1 to 11 who have acid reflux disease. FDA said Thursday it approved liquid and delayed-release capsules of Nexium in doses of 10 milligrams or 20 milligrams for these youngsters. It is already approved in doses of 20 milligrams or 40 milligrams for those aged 12 to 17. Nexium, manufactured by AstraZeneca of …
February 28th 2008
Crystal Lake resident Peg Altenburg is sure that she was saved from having a heart attack.
February 28th 2008
QUESTION: My active 10 year-old boy was recently diagnosed with “vocal cord dysfunction.” He’s been seen by his pediatrician, a respiratory specialist, an ENT specialist and a speech pathologist. He has intense pain and difficulty breathing (like an asthmatic) with each 30- to 70-minute episode. It happens any time he exerts himself. Supposedly, the speech pathologist can help with breathing …
February 27th 2008
The prevalence of headache is higher in people with gastrointestinal (GI) symptoms such as nausea, acid reflux, diarrhea, and constipation, than in people who don’t have these bothersome symptoms, new research indicates.
February 27th 2008
Health Canada has completed a review of safety information for Losec (omeprazole) and Nexium (esomeprazole) and found no increased cardiovascular risks.
February 27th 2008
Health Canada lifted its warning on Wednesday on two AstraZeneca drugs used to treat acid-related stomach disorders after it determined there was no obvious link between the treatments and heart attacks and cardiac deaths.
February 27th 2008
Health Canada’s review of Losec and Nexium – two prescription drugs that are used to treat acid-related stomach disorders – has shown mixed results, it was revealed Wednesday.
February 27th 2008
EndoGastric Solutions, the world leader in natural orifice surgery products and procedures, announces outstanding results at the completion of 1-year follow-up on GERD patients in the phase 2 multi-center study of the first generation transoral incisionless fundoplication (TIF 1) procedure and first-generation EsophyX device.
February 27th 2008
EndoGastric Solutions, the world leader in natural orifice surgery products and procedures, announces outstanding results at the completion of 1-year follow-up on GERD patients in the phase 2 multi-center study of the first generation transoral incisionless fundoplication (TIF 1) procedure and first-generation EsophyX device.